The Next Gen Immuno-Oncology Congress 2018 is dedicated to the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiome-derived immunotherapy.
Topics
- Immune Checkpoint Inhibitors and Combinations (PD-1, PD-L1, PD-L4)
- Neoantigens in personalized Cancer Immunotherapy
- (Preclinical models for Immunecheckpoint modulators)
- Preclinical and Translational Immuno-Oncology Developments
- Biomarkers and Cancer Vaccines
- Neoantigen Discovery by Next-Generation Sequencing
- Microbiome in Cancer Immunotherapy (Targets and Challenges)
- CAR-T cell therapy, Dendritic Cell Therapy
- Tumor associated Macrophages as treatment in IO
- Oncolytic viruses
- Tumor microenvironment
- Technologies for personalized TCR engineered cancer immunotherapies
Who should Attend
Senior attendees with responsibilities in:
- Cellular Therapy
- Neoantigens and Microbiome
- Immune Checkpoint Inhibitors
